Ozogamicin

Star0

DB20631InvestigationalSmall molecule

Ozogamicin is a small molecule drug. Ozogamicin has a monoisotopic molecular weight of 1680.47 Da.

Mechanism: Pharmacologically active on B-cell receptor CD22 and Myeloid cell surface antigen CD33
Curator reviewed
Formula / weight: C₇₃H₉₇IN₆O₂₅S₃ · 1681.68 g/mol (avg)

Resolves to

Compound

UNIIEDM24GA51FCAS400046-53-9

Structure

InChIKeyHNMATTJJEPZZMM-BPKVFSPJSA-NSMILES

[H][C@@]1(C[C@H](OC)[C@H](CO1)N(CC)C(C)=O)O[C@@H]1[C@@H](O)[C@H](NO[C@H]2C[C@H](O)[C@H](SC(=O)C3=C(C)C(I)=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)[C@H]4O)C(OC)=C3OC)[C@@H](C)O2)[C@@H](C)O[C@@]1([H])O[C@H]1C#C\C=C/C#C[C@]2(O)CC(=O)C(NC(=O)OC)=C1\C2=C/CSSC(C)(C)CC(=O)N\N=C(/C)C1=CC=C(OCCCC(N)=O)C=C1

Targets

P20273CD22P20138CD33

What you can answer from here — as of August 31, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ozogamicin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account